Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate
With these results, Breyanzi has now demonstrated clinically meaningful benefit across the broadest array of B-cell malignancies of any CD19-directed CAR T cell therapy, underscoring the company’s leadership in advancing innovative therapies for many types of...Why Wisconsin Should Be the Next U.S. Regional Tech Hub
By: Lisa Johnson In this In Business article, Lisa Johson, Bioforward’s CEO, talks about how the U.S. government’s CHIPS and Science Act is planning to give $10 billion dollars to six regional innovation and technology hubs across the country, and the...Pall Life Sciences is now part of Cytiva!
We’re thrilled to share the news — Cytiva and the Life Sciences business of Pall have united under the Cytiva name! With a mission to advance therapeutics from discovery to delivery, combining our organizations just makes sense. Together, we bring broad and deep...New Atomic-Scale Understanding of Catalysis Could Unlock Massive Energy Savings
In an advance they consider a breakthrough in computational chemistry research, University of Wisconsin–Madison chemical engineers have developed a model of how catalytic reactions work at the atomic scale. This understanding could allow engineers and chemists to...Events
June 2023
Jun 05 - 08 2023
BIO International Convention
Boston Convention & Exhibition Center
Jun 05 - 09 2023
2023 Morgridge Entrepreneurial Bootcamp
Jun 20 - 22 2023
NIH SBIR/STTR Proposal Workshop
Jun 27 - 29 2023
Summerfest Tech 2023
Potawatomi Hotel & Casino
July 2023
Jul 22 2023
2023 Unity Picnic
October 2023
Oct 10 2023
Wisconsin Innovation Awards
Oct 17 2023
Wisconsin Biohealth Summit
Overture Center for the Arts
December 2023
Dec 12 2023
2023 End of Year Celebration
No event found!